World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
77003
World Ranking
6636
National Ranking
3516

Antonio C. Wolff publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Antonio C. Wolff sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 552 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Antonio C. Wolff D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Antonio C. Wolff sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 105 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Antonio C. Wolff is affiliated with Johns Hopkins University in the United States and has contributed extensively to research in medicine, particularly within the fields of oncology and cancer biology. Their work spans multiple subfields including oncology, cancer research, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, and genetics.

The research topics addressed by Wolff center primarily on breast cancer treatment studies, HER2/EGFR in cancer research, advanced breast cancer therapies, cancer treatment and pharmacology, cancer genomics and diagnostics, cancer survivorship and care, and monoclonal and polyclonal antibodies research.

Wolff has published frequently in several notable scientific venues, reflecting the focus of their research domains. The top publication outlets include:

  • Journal of Clinical Oncology
  • Cancer Research
  • UNC Libraries
  • Annals of Oncology
  • Clinical Cancer Research

Significant recent papers authored or coauthored by Wolff illustrate both clinical and molecular aspects of breast cancer diagnostics and therapeutics. Key publications include:

  • "Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update" (2020, Journal of Clinical Oncology)
  • "TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes" (2020, Journal of Clinical Oncology)
  • "Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update" (2023, Journal of Clinical Oncology)
  • "Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update" (2020, Archives of Pathology & Laboratory Medicine)
  • "Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study" (2021, The Lancet Oncology)

The scientist has collaborated frequently with other researchers in the oncology field. The most frequent coauthors include:

  • Ian E. Krop
  • Eric P. Winer
  • Vered Stearns
  • Lisa A. Carey
  • Mothaffar F. Rimawi

Best Publications

  • American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    M. Elizabeth H. Hammond;Daniel F Hayes;Mitch Dowsett;D Craig Allred

  • American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

    Antonio C Wolff;M Elizabeth Hale Hammond;Kimberly H Allison;Brittany E Harvey

  • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

    Antonio C. Wolff;M. Elizabeth H Hammond;David G. Hicks;Mitch Dowsett

  • Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

    Antonio C. Wolff;M. Elizabeth Hale Hammond;Kimberly H. Allison;Brittany E. Harvey

  • American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

    Gary H. Lyman;Armando E. Giuliano;Mark R. Somerfield;Al B. Benson

  • 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

    Thomas J. Smith;James Khatcheressian;Gary H. Lyman;Howard Ozer

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

    Sylvia Adams;Robert J. Gray;Sandra Demaria;Lori Goldstein

  • Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

    Joseph A. Sparano;Joseph A. Sparano;Molin Wang;Silvana Martino;Vicky Jones

  • Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.

    Bethany B. Barone;Hsin Chieh Yeh;Claire F. Snyder;Kimberly S. Peairs

  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

    Kimberly H. Allison;M. Elizabeth H. Hammond;Mitchell Dowsett;Shannon E. McKernin

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    M. Elizabeth H. Hammond;Daniel F. Hayes;Antonio C. Wolff;Pamela B. Mangu

  • Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

    James L. Khatcheressian;Patricia Hurley;Elissa Bantug;Laura J. Esserman

  • Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Paul E. Goss;James N. Ingle;Kathleen I. Pritchard;Nicholas J. Robert

  • American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting

    James L. Khatcheressian;Antonio C. Wolff;Thomas J. Smith;Eva Grunfeld

  • Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Harold J. Burstein;Anthony D. Elias;Hope S. Rugo;Melody A. Cobleigh

  • Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

    Hyman B. Muss;Hyman B. Muss;Donald A. Berry;Constance T. Cirrincione;Maria Theodoulou

Frequent Co-Authors

Vered Stearns
Vered Stearns Johns Hopkins University
Steven N. Goodman
Steven N. Goodman Stanford University
Giovanni Parmigiani
Giovanni Parmigiani Harvard University
Eric B. Bass
Eric B. Bass Johns Hopkins University
Eric P. Winer
Eric P. Winer Yale University
Ian E. Krop
Ian E. Krop Harvard University
Nancy E. Davidson
Nancy E. Davidson University of Washington
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
Harold J. Burstein
Harold J. Burstein Harvard University
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers a variety of online degree options for those seeking flexibility and affordability while advancing their careers. Many students consider online nurse practitioner programs to gain advanced clinical skills and more responsibility as healthcare providers.

For those just starting out, exploring affordable nursing programs online is a practical way to enter the healthcare industry without incurring massive debt. These programs often provide pathways to earning a Registered Nurse (RN) license.

Nurses aiming to elevate their educational qualifications may pursue a terminal degree through phd nursing programs, focusing on research, leadership, or education roles. Meanwhile, working RNs can seamlessly advance their credentials via cheapest rn to bsn online programs that are designed for convenience and cost-effectiveness.

Each of these online pathways can help pave the way for further specialization, career progression, and increased salary potential in the U.S. healthcare sector.

Best Scientists Citing Antonio C. Wolff

Trending Scientists

Recently Published Articles